Vildagliptin Veresus Liraglutide - Patient Preference After Receiving Both Medications (PREFER)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01518101
First received: January 22, 2012
Last updated: August 16, 2013
Last verified: August 2013

January 22, 2012
August 16, 2013
January 2012
October 2012   (final data collection date for primary outcome measure)
Proportion of patients preferring each treatment regimen [ Time Frame: At week 24 ] [ Designated as safety issue: No ]
Individual patient preference will be assessed by a two-choice question.
Same as current
Complete list of historical versions of study NCT01518101 on ClinicalTrials.gov Archive Site
  • Number of patients with treatment satisfaction for each treatment measured by Diabetes Treatment Satisfaction Questionnaire (TSQM-9) [ Time Frame: week 12, Week 24 ] [ Designated as safety issue: No ]
    The TSQM -9 is a psychometrically measure of the major dimensions of patients' satisfaction with medication. It provides scores on 3 scales: effectiveness (3 items), convenience (3 items) and global satisfaction (3 items).
  • Number of patients responding to subjective reasons of preference to each treatment [ Time Frame: Week 12, week 24 ] [ Designated as safety issue: No ]
    Individual patient preference will be assessed by a two-choice question. Patients will also be asked to specify the reason for preference. A specific questionnaire for the preference reasons will be provided.
  • Number of patients with adverse event, serious adverse events and death [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
    Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.
  • Change from baseline in fasting plasma glucose at 12 weeks and 24 weeks [ Time Frame: From Baseline to 12 weeks and 24 weeks ] [ Designated as safety issue: No ]
    Blood glucose measurements will be performed at baseline, week 12 and week 24 visits.
  • Change From Baseline in Hemoglobin A1c (HbA1c) at week 12 and week 24 [ Time Frame: From Baseline to 12 weeks and 24 weeks ] [ Designated as safety issue: No ]
    HbA1c measurements will be performed at baseline, week 12 and week 24 visits.
  • Investigator preference and subjective reasons of preference to each treatment [ Time Frame: Week 12, week 24 ] [ Designated as safety issue: No ]
    Investigator preference will be assessed by a two-choice question. Investigator will also be asked to specify the reason for preference. A specific questionnaire for the preference reasons will be provided.
Same as current
Not Provided
Not Provided
 
Vildagliptin Veresus Liraglutide - Patient Preference After Receiving Both Medications
A Randomized, Open-label, Cross-over Study to Evaluate Patient Preferences for Eucreas® Versus Victoza® as add-on to Metformin in Type 2 Diabetes Mellitus Patients Who Did Not Have Adequate Glycaemic Control With Metformin.

Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagonlike peptide-1 (GLP-1) mimetics or analogs, which rely on the gastrointestinal hormones that are part of the incretin system for the treatment of T2DM, provide a therapeutic alternative to common oral antihyperglycemic agents (eg, sulfonylureas, thiazolidinediones). Although GLP-1 analogs and DPP-4 inhibitor medications are effective, there are differences between these products, including method of administration (injectable versus oral). Previous studies have shown that patients prefer additional oral agents over injectable agents because of fear of injections and the desire to avoid them. Patient preference is both clinically and financially important, as it can have long-term implications in terms of patients' motivation and insight into their disease state and its treatment, which might have a direct impact on the patient's compliance and treatment adherence. The aim of the current study is to evaluate the proportion of T2DM patients preferring oral anti-diabetic treatment with vildagliptin + metformin versus an injectable anti-diabetic treatment with liraglutide after 4 weeks of treatment with each medication.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Type 2 Diabetes
  • Drug: Vildagliptin/ Metformin
    Single pill combination of Vildagliptin/ Metformin (50/1000 mg).
  • Drug: Liraglutide
    1.2 mg once daily by commercially available injection pens
  • Drug: Metformin
    1000 mg tablets twice daily
  • Experimental: Vildagliptin/Metformin followed by Liraglutide+Metformin
    In period I, Patients receiving vildagliptin will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for 12 weeks. In period II, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid for the first week (week 13 - week 14) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid.
    Interventions:
    • Drug: Vildagliptin/ Metformin
    • Drug: Liraglutide
    • Drug: Metformin
  • Experimental: Liraglutide + Metformin followed by Vildagliptin/Metformin
    In period I, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid (twice daily) for the first week (week 0 - week 1) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid (week 2 -12). In period II, patients will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for next 12 weeks.
    Interventions:
    • Drug: Vildagliptin/ Metformin
    • Drug: Liraglutide
    • Drug: Metformin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
62
October 2012
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with type 2 diabetes
  • Metformin monotherapy > 12 weeks
  • Hemoglobin A1c (HbA1c) > 6.5 % and < 9.0 %
  • Body mass Index (BMI) 19-35 (kg/m²)

Exclusion Criteria:

  • acute diseases at randomization
  • kidney diseases with creatinin > 120 µmol/l, glomerular filtration rate (GFR) <50 ml/min
  • contraindication for Gliptins or glucagon-like-peptide-analogues according to the respective Summary of Product Characteristics (SmPC)
  • previous use of dipeptidyl peptidase-4-inhibitors and GLP-1-mimetics

Other protocol-defined inclusion/exclusion criteria may apply.

Both
40 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01518101
CLMF237ADE03, 2011-003818-16
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP